Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
Barbara Ann Karmanos Cancer Institute
Emory University
Weill Medical College of Cornell University
University of Massachusetts, Worcester
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Bristol-Myers Squibb
European Society for Blood and Marrow Transplantation